By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sangamo Therapeutics (Formerly Known As Sangamo BioSciences, Inc.) 

501 Canal Boulevard
Suite A100
Richmond  California  94804  U.S.A.
Phone: 510-970-6000 Fax: 510-236-8951


Key Statistics

Ownership: Public

Web Site: Sangamo Therapeutics
Symbol: SGMO


Company News
Sangamo Therapeutics (SGMO) Announces Fourth Quarter And Full Year 2016 Conference Call And Webcast 2/22/2017 8:42:56 AM
Sangamo (SGMO) Release: Pharma Receives Orphan Drug Designation From The FDA For SB-318 Genome Editing Treatment For MPS I 1/11/2017 6:00:10 AM
Sangamo (SGMO) Release: Company Presents Latest Advances In Zinc Finger Nuclease Platform Technology At Keystone Symposium On Precision Genome Engineering 1/10/2017 6:46:05 AM
Sangamo (SGMO) Announces FDA Clearance Of Investigational New Drug Application For SB-525 Gene Therapy Program For Hemophilia A 1/5/2017 6:33:43 AM
Sangamo (SGMO) Presents Hemophilia A Program Data At The 2016 American Society of Hematology Meeting 12/6/2016 8:30:13 AM
Sangamo (SGMO) Makes Key Leadership Appointments To Strengthen Clinical And Commercial Capabilities 12/1/2016 11:38:26 AM
The Link Between Bay Area's Sangamo (SGMO) and Biogen (BIIB)'s Spinoff Bioverativ 11/30/2016 5:52:29 AM
Sangamo (SGMO) Founder Appointed Buck Institute for Age Research's New President and CEO 10/31/2016 6:26:59 AM
Sangamo (SGMO) Reports Third Quarter 2016 Financial Results 10/27/2016 9:55:05 AM
Sangamo (SGMO) Announces Third Quarter 2016 Conference Call And Webcast 10/20/2016 9:45:42 AM